Skip to content
OpenCapital
Get started

Incyte INCY Net gains (losses) on investments

Net gains (losses) on investments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$180K-1,536%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.5B+132%
Total debt$32.7M-22.9%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$23.51B+73.1%
Enterprise value$19.01B+62.9%
P/E14.6×-1.0×
P/S4×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin28.2%+19.7pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0×0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's net gains (losses) on investments?
Incyte (INCY) reported net gains (losses) on investments of $6.59M in Q1 2026.
How has Incyte's net gains (losses) on investments changed year-over-year?
Incyte's net gains (losses) on investments increased by 590.8% year-over-year, from -$1.34M to $6.59M.
What is the long-term trend for Incyte's net gains (losses) on investments?
Over 3 years (2022 to 2025), Incyte's net gains (losses) on investments has grown at a -37.6% compound annual growth rate (CAGR), from -$87.59M to $21.31M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.